sulfasalazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
phenylazosalicylic acid derivatives antibacterial 2525 599-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • salazosulfapyridine
  • salicylazosulfapyridine
  • sulphasalazine
  • azulfidine
  • sulfasalazine
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
  • Molecular weight: 398.39
  • Formula: C18H14N4O5S
  • CLOGP: 3.99
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 141.31
  • ALOGS: -3.93
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O
2 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 167.34 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.26 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 20, 1950 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 13603.24 58.84 3690 4016 97934 2252445
Rheumatoid arthritis 9756.62 58.84 2099 5607 17041 2333338
Drug intolerance 6592.20 58.84 1446 6260 12271 2338108
Drug hypersensitivity 4286.80 58.84 1321 6385 45322 2305057
Treatment failure 4061.10 58.84 873 6833 6366 2344013
Joint swelling 3881.77 58.84 985 6721 15834 2334545
Contraindicated product administered 3439.16 58.84 658 7048 2363 2348016
Arthralgia 2514.74 58.84 925 6781 53360 2297019
Therapeutic product effect incomplete 2381.55 58.84 610 7096 9921 2340458
Pain 2364.38 58.84 916 6790 60941 2289438
Synovitis 2233.12 58.84 452 7254 2274 2348105
Loss of personal independence in daily activities 2216.91 58.84 505 7201 4806 2345573
Condition aggravated 2072.12 58.84 702 7004 31277 2319102
Rash 1934.16 58.84 786 6920 58772 2291607
Therapeutic product effect decreased 1795.57 58.84 491 7215 10298 2340081
Abdominal discomfort 1723.22 58.84 529 7177 16927 2333452
Musculoskeletal stiffness 1634.31 58.84 469 7237 11778 2338601
C-reactive protein abnormal 1575.91 58.84 278 7428 521 2349858
Nausea 1497.81 58.84 800 6906 111389 2238990
Fatigue 1417.66 58.84 705 7001 84168 2266211
Alopecia 1197.37 58.84 426 7280 21575 2328804
Peripheral swelling 1170.60 58.84 396 7310 17201 2333178
Arthropathy 981.04 58.84 282 7424 7034 2343345
Pemphigus 977.54 58.84 181 7525 495 2349884
Systemic lupus erythematosus 975.59 58.84 250 7456 3971 2346408
Pain in extremity 969.66 58.84 440 7266 42100 2308279
Swelling 965.90 58.84 337 7369 16013 2334366
C-reactive protein increased 950.96 58.84 266 7440 5989 2344390
Hepatic enzyme increased 920.64 58.84 287 7419 9515 2340864
Red blood cell sedimentation rate abnormal 911.41 58.84 164 7542 359 2350020
Infection 907.38 58.84 330 7376 17699 2332680
Hand deformity 821.09 58.84 169 7537 917 2349462
Mobility decreased 797.82 58.84 251 7455 8559 2341820
Glossodynia 781.46 58.84 180 7526 1765 2348614
Red blood cell sedimentation rate increased 775.12 58.84 182 7524 1955 2348424
Psoriatic arthropathy 760.05 58.84 202 7504 3712 2346667
Blood iron abnormal 709.79 58.84 113 7593 61 2350318
Hypersensitivity 671.20 58.84 286 7420 23307 2327072
Rheumatoid factor positive 669.43 58.84 126 7580 386 2349993
Osteoarthritis 662.33 58.84 206 7500 6740 2343639
Rheumatoid nodule 639.64 58.84 125 7581 493 2349886
Diarrhoea 632.95 58.84 417 7289 83147 2267232
Pneumonia 624.83 58.84 343 7363 48953 2301426
Headache 618.96 58.84 405 7301 79774 2270605
Gait disturbance 610.41 58.84 264 7442 22281 2328098
Vomiting 602.47 58.84 382 7324 71220 2279159
Bone erosion 588.91 58.84 115 7591 451 2349928
Musculoskeletal pain 553.76 58.84 201 7505 10629 2339750
Malaise 552.05 58.84 330 7376 55255 2295124
Anti-cyclic citrullinated peptide antibody positive 537.77 58.84 91 7615 112 2350267
Interstitial lung disease 533.77 58.84 180 7526 7632 2342747
Disability 516.14 58.84 110 7596 722 2349657
Knee arthroplasty 510.60 58.84 139 7567 2796 2347583
Arthritis 509.49 58.84 185 7521 9783 2340596
Inflammation 508.05 58.84 164 7542 6049 2344330
Grip strength decreased 500.84 58.84 112 7594 945 2349434
Liver function test abnormal 450.78 58.84 157 7549 7333 2343046
Drug reaction with eosinophilia and systemic symptoms 448.37 58.84 145 7561 5373 2345006
Adverse drug reaction 446.64 58.84 160 7546 8123 2342256
Liver function test increased 434.61 58.84 124 7582 2977 2347402
Sleep disorder due to general medical condition, insomnia type 432.40 58.84 83 7623 290 2350089
Non-Hodgkin's lymphoma 417.34 58.84 94 7612 821 2349558
Gastrointestinal disorder 416.67 58.84 155 7551 8762 2341617
Transplant dysfunction 404.34 58.84 80 7626 340 2350039
Infusion related reaction 395.35 58.84 153 7553 9643 2340736
Joint stiffness 394.28 58.84 122 7584 3901 2346478
Granuloma skin 380.58 58.84 63 7643 60 2350319
Drug eruption 358.38 58.84 108 7598 3151 2347228
Blood parathyroid hormone decreased 349.88 58.84 64 7642 158 2350221
Pyrexia 344.88 58.84 243 7463 53465 2296914
Sciatica 343.28 58.84 95 7611 2030 2348349
Off label use 339.45 58.84 273 7433 73325 2277054
Coeliac disease 333.78 58.84 77 7629 755 2349624
Nail disorder 330.13 58.84 81 7625 1055 2349324
Lung disorder 327.15 58.84 118 7588 6094 2344285
Musculoskeletal disorder 326.96 58.84 95 7611 2433 2347946
Ulcer 326.61 58.84 89 7617 1791 2348588
Visual impairment 324.92 58.84 140 7566 11615 2338764
Fibromyalgia 322.97 58.84 100 7606 3200 2347179
Sleep disorder 322.13 58.84 118 7588 6371 2344008
Hip arthroplasty 321.30 58.84 88 7618 1806 2348573
Transplant rejection 315.31 58.84 79 7627 1127 2349252
Panniculitis 310.57 58.84 67 7639 468 2349911
Tenderness 306.35 58.84 85 7621 1833 2348546
Sinusitis 306.19 58.84 149 7557 16377 2334002
Ovarian cyst 303.98 58.84 85 7621 1888 2348491
Therapeutic response decreased 295.89 58.84 114 7592 7081 2343298
Onychomycosis 290.02 58.84 64 7642 503 2349876
Impaired work ability 288.10 58.84 80 7626 1730 2348649
Acne 276.39 58.84 88 7618 3088 2347291
Wound 268.30 58.84 83 7623 2645 2347734
Joint effusion 267.03 58.84 70 7636 1206 2349173
Hypertension 266.46 58.84 161 7545 27200 2323179
Anaphylactic reaction 266.16 58.84 115 7591 9590 2340789
Adverse event 264.61 58.84 107 7599 7552 2342827
Hepatotoxicity 252.39 58.84 84 7622 3397 2346982
Skin ulcer 251.31 58.84 87 7619 3972 2346407
Product use issue 250.45 58.84 118 7588 12051 2338328
Neoplasm malignant 250.40 58.84 92 7614 5001 2345378
Foot deformity 249.44 58.84 73 7633 1916 2348463
Nodule 245.63 58.84 74 7632 2152 2348227
Alanine aminotransferase increased 243.33 58.84 121 7585 13911 2336468
Deformity 242.62 58.84 54 7652 443 2349936
Skin necrosis 236.43 58.84 62 7644 1069 2349310
Human antichimeric antibody positive 235.93 58.84 36 7670 6 2350373
Injection site reaction 235.29 58.84 121 7585 14931 2335448
Body height below normal 234.97 58.84 41 7665 68 2350311
Dry eye 234.16 58.84 82 7624 3874 2346505
Joint range of motion decreased 232.21 58.84 68 7638 1788 2348591
Erythema 221.80 58.84 139 7567 25020 2325359
Breast cancer stage III 218.25 58.84 41 7665 123 2350256
International normalised ratio fluctuation 217.93 58.84 46 7660 285 2350094
Enthesopathy 217.51 58.84 41 7665 126 2350253
Osteoporosis 214.24 58.84 79 7627 4335 2346044
Abdominal pain 214.15 58.84 153 7553 34221 2316158
Back pain 211.31 58.84 147 7559 31512 2318867
Synovial fluid analysis 207.93 58.84 31 7675 0 2350379
Joint destruction 205.72 58.84 44 7662 293 2350086
Finger deformity 204.42 58.84 52 7654 790 2349589
Basal cell carcinoma 203.40 58.84 67 7639 2620 2347759
Presbyacusis 201.63 58.84 33 7673 27 2350352
Hepatitis 199.95 58.84 83 7623 6254 2344125
Hypercalcaemia 197.68 58.84 65 7641 2527 2347852
Tenosynovitis 197.59 58.84 46 7660 470 2349909
Adverse reaction 193.60 58.84 57 7649 1527 2348852
Synovial cyst 188.13 58.84 49 7657 821 2349558
Bursitis 187.35 58.84 58 7648 1850 2348529
Aspartate aminotransferase increased 187.30 58.84 98 7608 12514 2337865
Diverticulitis 185.51 58.84 70 7636 4095 2346284
Abdominal pain upper 184.45 58.84 118 7588 21982 2328397
Neck pain 184.42 58.84 83 7623 7614 2342765
Stomatitis 183.97 58.84 89 7617 9621 2340758
Stress 182.89 58.84 80 7626 6858 2343521
Tenosynovitis stenosans 181.22 58.84 34 7672 101 2350278
Rash pruritic 179.73 58.84 81 7625 7454 2342925
Osteopenia 178.17 58.84 56 7650 1879 2348500
General physical health deterioration 176.78 58.84 98 7608 14041 2336338
Pruritus 176.46 58.84 150 7556 43190 2307189
Nasopharyngitis 174.79 58.84 114 7592 21942 2328437
Bronchitis 171.30 58.84 95 7611 13619 2336760
Contusion 168.98 58.84 92 7614 12718 2337661
Drug tolerance decreased 167.74 58.84 36 7670 244 2350135
Adrenal insufficiency 165.06 58.84 49 7657 1351 2349028
Crohn's disease 163.36 58.84 73 7633 6582 2343797
Depression 163.16 58.84 120 7586 28012 2322367
Dizziness 163.01 58.84 164 7542 58501 2291878
Antibody test positive 160.16 58.84 35 7671 261 2350118
Cushingoid 159.59 58.84 40 7666 570 2349809
Septic shock 159.28 58.84 73 7633 6981 2343398
Psoriasis 157.39 58.84 97 7609 16911 2333468
Pleural fibrosis 155.91 58.84 32 7674 169 2350210
Therapy non-responder 155.66 58.84 75 7631 8029 2342350
Wheelchair user 155.29 58.84 37 7669 421 2349958
Carpal tunnel syndrome 155.27 58.84 51 7655 1974 2348405
Dyspepsia 153.30 58.84 79 7627 9765 2340614
Scleritis 153.26 58.84 34 7672 274 2350105
Onychomadesis 151.91 58.84 37 7669 465 2349914
Juvenile idiopathic arthritis 149.41 58.84 36 7670 431 2349948
Red blood cell sedimentation rate 148.15 58.84 23 7683 7 2350372
Thyroid disorder 146.79 58.84 46 7660 1527 2348852
Eye disorder 146.59 58.84 55 7651 3164 2347215
Arthrodesis 146.57 58.84 31 7675 194 2350185
Influenza like illness 146.03 58.84 82 7624 12032 2338347
Feeling jittery 145.49 58.84 48 7658 1884 2348495
Photophobia 145.24 58.84 50 7656 2239 2348140
X-ray abnormal 144.86 58.84 29 7677 132 2350247
Obesity 143.68 58.84 45 7661 1491 2348888
Crepitations 141.53 58.84 37 7669 629 2349750
Groin pain 140.83 58.84 43 7663 1307 2349072
Multiple allergies 140.67 58.84 39 7667 836 2349543
Bone density decreased 140.21 58.84 43 7663 1327 2349052
Exostosis 139.96 58.84 43 7663 1335 2349044
Neck deformity 138.01 58.84 25 7681 57 2350322
Wheezing 137.67 58.84 64 7642 6320 2344059
Palpitations 137.54 58.84 88 7618 16368 2334011
Renal impairment 137.29 58.84 74 7632 10018 2340361
Polyarthritis 136.04 58.84 38 7668 838 2349541
Pleural thickening 135.96 58.84 25 7681 64 2350315
Deafness neurosensory 134.21 58.84 34 7672 507 2349872
Localised infection 134.09 58.84 50 7656 2826 2347553
Gastric disorder 132.04 58.84 53 7653 3657 2346722
Dermatitis allergic 130.90 58.84 45 7661 2006 2348373
Ankylosing spondylitis 130.32 58.84 35 7671 663 2349716
Blood cholesterol increased 130.23 58.84 58 7648 5183 2345196
Fear of injection 129.81 58.84 37 7669 880 2349499
Extremity contracture 128.92 58.84 25 7681 93 2350286
Pleuritic pain 127.96 58.84 34 7672 617 2349762
Bone density abnormal 126.80 58.84 31 7675 396 2349983
Spinal stenosis 126.21 58.84 40 7666 1378 2349001
Leukopenia 125.53 58.84 70 7636 10126 2340253
Cataract 123.58 58.84 58 7648 5850 2344529
Gait inability 123.14 58.84 58 7648 5897 2344482
Weight decreased 123.14 58.84 102 7604 28269 2322110
Pustular psoriasis 122.13 58.84 35 7671 849 2349530
Therapeutic product effect variable 120.71 58.84 25 7681 139 2350240
Back injury 119.46 58.84 35 7671 920 2349459
Antinuclear antibody positive 119.44 58.84 36 7670 1046 2349333
Mouth ulceration 119.17 58.84 50 7656 3862 2346517
Liver disorder 119.04 58.84 58 7648 6356 2344023
Glaucoma 118.46 58.84 42 7664 2053 2348326
Herpes zoster 117.63 58.84 66 7640 9659 2340720
Cough 117.29 58.84 106 7600 33011 2317368
Musculoskeletal deformity 115.83 58.84 19 7687 16 2350363
Fine motor skill dysfunction 114.47 58.84 27 7679 293 2350086
Foot fracture 113.08 58.84 44 7662 2794 2347585
Conjunctivitis 113.01 58.84 42 7664 2351 2348028
Blood pressure fluctuation 111.39 58.84 39 7667 1836 2348543
Neck mass 110.86 58.84 27 7679 339 2350040
White blood cell count decreased 110.73 58.84 80 7626 18128 2332251
Thrombosis 110.44 58.84 62 7644 9082 2341297
Asthenia 110.12 58.84 120 7586 46806 2303573
Ovarian neoplasm 109.69 58.84 24 7682 180 2350199
Muscle fatigue 109.57 58.84 27 7679 357 2350022
Unevaluable event 109.32 58.84 61 7645 8830 2341549
Lymphadenopathy 107.16 58.84 52 7654 5646 2344733
Tuberculin test positive 107.00 58.84 29 7677 569 2349810
Breast cancer 105.58 58.84 61 7645 9434 2340945
Dyspnoea 104.06 58.84 151 7555 78582 2271797
Flank pain 102.89 58.84 35 7671 1510 2348869
Blood magnesium increased 102.38 58.84 22 7684 150 2350229
Insomnia 102.17 58.84 88 7618 25699 2324680
Ocular hyperaemia 101.11 58.84 45 7661 4011 2346368
Dry mouth 99.77 58.84 56 7650 8197 2342182
Shoulder arthroplasty 98.90 58.84 25 7681 369 2350010
Pneumonitis 98.09 58.84 44 7662 3995 2346384
Bedridden 97.56 58.84 33 7673 1399 2348980
Myalgia 97.28 58.84 82 7624 23251 2327128
Lower limb fracture 96.34 58.84 36 7670 2045 2348334
Epigastric discomfort 95.09 58.84 26 7680 528 2349851
Swelling face 95.07 58.84 57 7649 9436 2340943
Physical disability 95.00 58.84 21 7685 166 2350213
Atelectasis 94.66 58.84 35 7671 1930 2348449
Photosensitivity reaction 94.47 58.84 37 7669 2390 2347989
Colitis microscopic 94.16 58.84 29 7677 907 2349472
Cyst 94.11 58.84 33 7673 1560 2348819
Rheumatoid factor negative 92.94 58.84 15 7691 10 2350369
Immobile 92.65 58.84 26 7680 583 2349796
Neutropenia 92.45 58.84 77 7629 21471 2328908
Blood creatinine increased 92.11 58.84 58 7648 10475 2339904
Drug-induced liver injury 92.08 58.84 41 7665 3658 2346721
Discomfort 90.78 58.84 45 7661 5114 2345265
Treatment noncompliance 90.70 58.84 46 7660 5488 2344891
Mucosal inflammation 90.25 58.84 45 7661 5179 2345200
Immunodeficiency 90.18 58.84 29 7677 1047 2349332
Pancytopenia 90.11 58.84 59 7647 11393 2338986
Skin lesion 88.76 58.84 41 7665 3984 2346395
Urticaria 88.48 58.84 79 7627 24182 2326197
Pyelonephritis 88.15 58.84 34 7672 2107 2348272
Pericarditis 87.54 58.84 31 7675 1509 2348870
Diabetes mellitus 85.58 58.84 49 7657 7446 2342933
Incorrect dosage administered 84.52 58.84 22 7684 367 2350012
Red blood cell count decreased 83.43 58.84 40 7666 4226 2346153
Dermatitis 81.22 58.84 33 7673 2347 2348032
Drug specific antibody 81.19 58.84 16 7690 66 2350313
Pulmonary toxicity 80.69 58.84 24 7682 665 2349714
Maternal exposure during pregnancy 80.65 58.84 61 7645 14802 2335577
Joint injury 80.63 58.84 33 7673 2391 2347988
Retinitis 80.61 58.84 16 7690 69 2350310
Skin reaction 79.68 58.84 31 7675 1966 2348413
Bone cyst 79.55 58.84 18 7688 160 2350219
Nephrolithiasis 75.14 58.84 38 7668 4505 2345874
Impaired healing 74.44 58.84 40 7666 5371 2345008
Mood swings 74.27 58.84 34 7672 3235 2347144
Pre-existing condition improved 72.93 58.84 21 7685 518 2349861
Thyroid neoplasm 72.88 58.84 22 7684 642 2349737
Osteosclerosis 72.38 58.84 19 7687 328 2350051
Fall 72.01 58.84 97 7609 47002 2303377
Joint dislocation 70.37 58.84 26 7680 1430 2348949
Candida infection 68.80 58.84 31 7675 2842 2347537
Pulmonary fibrosis 68.07 58.84 30 7676 2610 2347769
Scar 66.85 58.84 27 7679 1890 2348489
Eye pain 66.84 58.84 36 7670 4855 2345524
Tuberculosis 66.61 58.84 27 7679 1908 2348471
Bloody discharge 66.22 58.84 15 7691 134 2350245
Eye irritation 65.86 58.84 32 7674 3480 2346899
Malignant melanoma 65.85 58.84 27 7679 1965 2348414
Injury 65.49 58.84 38 7668 5916 2344463
Red cell distribution width decreased 65.14 58.84 13 7693 58 2350321
Pelvic fracture 64.42 58.84 24 7682 1351 2349028
Hypercholesterolaemia 64.14 58.84 25 7681 1593 2348786
Seronegative arthritis 63.92 58.84 13 7693 65 2350314
Mean platelet volume decreased 63.86 58.84 14 7692 106 2350273
Oral pain 63.84 58.84 31 7675 3366 2347013
Intraocular pressure increased 62.25 58.84 24 7682 1485 2348894
Ill-defined disorder 61.01 58.84 30 7676 3348 2347031
Agranulocytosis 60.15 58.84 30 7676 3452 2346927
Neuropathy peripheral 59.97 58.84 46 7660 11386 2338993

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 3317.93 55.76 967 1420 62834 1681560
Rheumatoid arthritis 1554.64 55.76 324 2063 4261 1740133
Drug intolerance 1364.42 55.76 306 2081 5756 1738638
Joint swelling 904.45 55.76 222 2165 6131 1738263
Contraindicated product administered 827.41 55.76 159 2228 1285 1743109
Synovitis 708.77 55.76 126 2261 619 1743775
Drug hypersensitivity 688.17 55.76 216 2171 14919 1729475
Treatment failure 681.71 55.76 165 2222 4236 1740158
Pain 634.85 55.76 234 2153 26423 1717971
C-reactive protein abnormal 596.97 55.76 94 2293 173 1744221
Apparent death 506.93 55.76 83 2304 217 1744177
Loss of personal independence in daily activities 502.01 55.76 115 2272 2284 1742110
Diverticulitis 435.98 55.76 102 2285 2223 1742171
Hand deformity 415.03 55.76 68 2319 178 1744216
Arthralgia 399.36 55.76 162 2225 23282 1721112
Arthropathy 329.91 55.76 85 2302 2782 1741612
C-reactive protein increased 329.00 55.76 99 2288 5786 1738608
Therapeutic product effect incomplete 323.36 55.76 96 2291 5352 1739042
Renal failure 318.62 55.76 132 2255 19885 1724509
Condition aggravated 298.26 55.76 128 2259 21022 1723372
Nausea 292.32 55.76 167 2220 51029 1693365
Therapeutic product effect decreased 288.63 55.76 91 2296 6206 1738188
Enthesopathy 287.90 55.76 44 2343 58 1744336
Alopecia 239.34 55.76 70 2317 3683 1740711
Pulmonary embolism 234.15 55.76 94 2293 12965 1731429
Off label use 225.16 55.76 128 2259 38443 1705951
Deep vein thrombosis 222.32 55.76 84 2303 9836 1734558
Rash 214.00 55.76 124 2263 38569 1705825
Lymphadenopathy 211.53 55.76 65 2322 4049 1740345
Headache 211.08 55.76 118 2269 34258 1710136
Tenosynovitis 208.93 55.76 39 2348 257 1744137
Musculoskeletal stiffness 204.46 55.76 69 2318 5807 1738587
Gastrointestinal disorder 202.35 55.76 65 2322 4683 1739711
Infection 197.58 55.76 82 2305 12278 1732116
Lymphoma 192.62 55.76 52 2335 2030 1742364
Liver function test increased 183.43 55.76 47 2340 1492 1742902
Red blood cell sedimentation rate increased 173.45 55.76 42 2345 1051 1743343
Onychoclasis 173.26 55.76 32 2355 197 1744197
Mobility decreased 171.08 55.76 55 2332 3965 1740429
Musculoskeletal pain 170.21 55.76 58 2329 5016 1739378
Drug reaction with eosinophilia and systemic symptoms 166.33 55.76 57 2330 5013 1739381
Interstitial lung disease 160.46 55.76 66 2321 9630 1734764
Psoriatic arthropathy 155.69 55.76 45 2342 2258 1742136
Nodule 155.58 55.76 37 2350 855 1743539
Tooth loss 152.33 55.76 34 2353 587 1743807
Alanine aminotransferase increased 145.46 55.76 66 2321 12212 1732182
Herpes zoster 144.47 55.76 50 2337 4523 1739871
Pulmonary thrombosis 142.76 55.76 34 2353 790 1743604
Peripheral swelling 141.20 55.76 57 2330 7914 1736480
Tongue disorder 134.06 55.76 30 2357 524 1743870
Joint range of motion decreased 133.13 55.76 32 2355 774 1743620
Pyrexia 124.60 55.76 95 2292 46305 1698089
Drug tolerance decreased 124.43 55.76 23 2364 142 1744252
Erythema 124.35 55.76 62 2325 14126 1730268
Impaired work ability 122.87 55.76 32 2355 1081 1743313
Fatigue 119.13 55.76 96 2291 50685 1693709
Hip arthroplasty 118.88 55.76 29 2358 747 1743647
Ankylosing spondylitis 118.26 55.76 29 2358 764 1743630
Bone erosion 117.11 55.76 23 2364 204 1744190
Knee arthroplasty 113.73 55.76 29 2358 899 1743495
Pulmonary fibrosis 109.46 55.76 35 2352 2469 1741925
Alanine aminotransferase abnormal 109.36 55.76 22 2365 223 1744171
Arthritis 108.47 55.76 39 2348 3936 1740458
Pain in extremity 103.58 55.76 60 2327 18412 1725982
Arthritis bacterial 102.13 55.76 25 2362 653 1743741
Gastric disorder 102.00 55.76 31 2356 1847 1742547
Tendonitis 101.25 55.76 29 2358 1404 1742990
Aspartate aminotransferase increased 100.09 55.76 49 2338 10707 1733687
Swelling 96.82 55.76 42 2345 6954 1737440
Rheumatoid factor positive 93.99 55.76 16 2371 56 1744338
Hepatic enzyme abnormal 93.47 55.76 22 2365 484 1743910
Hypersensitivity 92.46 55.76 46 2341 10398 1733996
Malaise 89.06 55.76 65 2322 29500 1714894
Sleep disorder due to general medical condition, insomnia type 89.01 55.76 17 2370 128 1744266
Bladder transitional cell carcinoma 87.45 55.76 20 2367 386 1744008
Polyarthritis 87.16 55.76 21 2366 512 1743882
Foot deformity 84.49 55.76 20 2367 451 1743943
Abdominal discomfort 83.34 55.76 41 2346 9040 1735354
Back pain 82.69 55.76 50 2337 16563 1727831
Neck mass 81.94 55.76 17 2370 203 1744191
Thrombosis 81.29 55.76 38 2349 7483 1736911
Sepsis 80.38 55.76 52 2335 19386 1725008
Stomatitis 79.86 55.76 34 2353 5370 1739024
Agranulocytosis 78.80 55.76 30 2357 3546 1740848
Terminal state 78.33 55.76 21 2366 793 1743601
Prerenal failure 77.92 55.76 17 2370 262 1744132
Diarrhoea 76.75 55.76 77 2310 53775 1690619
Osteoarthritis 75.89 55.76 26 2361 2270 1742124
Intentional product use issue 75.35 55.76 27 2360 2692 1741702
Back disorder 74.38 55.76 21 2366 963 1743431
Thrombocytosis 73.71 55.76 19 2368 614 1743780
Insomnia 73.38 55.76 46 2341 16230 1728164
Neoplasm malignant 73.17 55.76 30 2357 4309 1740085
Immobile 72.64 55.76 17 2370 364 1744030
Joint arthroplasty 70.48 55.76 13 2374 79 1744315
Feeling abnormal 69.82 55.76 39 2348 11127 1733267
Lymphoedema 69.39 55.76 17 2370 445 1743949
Red blood cell sedimentation rate abnormal 69.27 55.76 13 2374 88 1744306
Cytology abnormal 68.74 55.76 11 2376 23 1744371
Joint contracture 66.88 55.76 14 2373 175 1744219
Disability 66.32 55.76 17 2370 537 1743857
Dyspepsia 65.90 55.76 29 2358 4956 1739438
Abscess 60.41 55.76 21 2366 1913 1742481
Blood albumin decreased 59.71 55.76 20 2367 1628 1742766
Axial spondyloarthritis 59.20 55.76 9 2378 11 1744383
Photosensitivity reaction 58.53 55.76 20 2367 1730 1742664
Depression 57.79 55.76 40 2347 16629 1727765
Urticaria 56.13 55.76 35 2352 12206 1732188

Pharmacologic Action:

SourceCodeDescription
ATC A07EC01 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFLAMMATORY AGENTS
Aminosalicylic acid and similar agents
FDA EPC N0000175781 Aminosalicylate
FDA CS M0000971 Aminosalicylic Acids
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:88188 drug allergen
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:55324 gastrointestinal drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ulcerative colitis indication 64766004 DOID:8577
Rheumatoid arthritis indication 69896004 DOID:7148
Juvenile rheumatoid arthritis indication 410795001
Collagenous colitis off-label use 19311003 DOID:0060183
Psoriasis with arthropathy off-label use 33339001
Crohn's disease off-label use 34000006
Systemic sclerosis off-label use 89155008 DOID:418
Urinary tract obstruction contraindication 7163005 DOID:5200
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Gastrointestinal obstruction contraindication 126765001
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Porphyria contraindication 418470004
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.28 acidic
pKa2 8.93 acidic
pKa3 11.45 acidic
pKa4 1.48 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cyclooxygenase Enzyme INHIBITOR CHEMBL CHEMBL
Arachidonate 5-lipoxygenase Enzyme INHIBITOR WOMBAT-PK CHEMBL
Thromboxane-A synthase Enzyme IC50 4.71 DRUG MATRIX
Interstitial collagenase Enzyme IC50 4.63 DRUG MATRIX
Mitogen-activated protein kinase 1 Kinase IC50 5.20 DRUG MATRIX
Acetyl-CoA acetyltransferase, mitochondrial Enzyme WOMBAT-PK
Carbonic anhydrase 2 Enzyme Ki 5.06 CHEMBL
Cystine/glutamate transporter Transporter IC50 4.52 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.16 CHEMBL
Proton-coupled folate transporter Transporter INHIBITOR IC50 4.20 IUPHAR
Caspase-1 Enzyme IC50 4.54 DRUG MATRIX
Androgen receptor Transcription factor Ki 4.53 DRUG MATRIX
Aldose reductase Enzyme IC50 4.77 DRUG MATRIX

External reference:

IDSource
4017897 VUID
N0000146249 NUI
C0036078 UMLSCUI
D00448 KEGG_DRUG
3XC8GUZ6CB UNII
2210 INN_ID
45844004 SNOMEDCT_US
4017897 VANDF
9524 RXNORM
387248006 SNOMEDCT_US
5528 MMSL
2061 MMSL
d00379 MMSL
002832 NDDF
CHEMBL421 ChEMBL_ID
DB00795 DRUGBANK_ID
SAS PDB_CHEM_ID
CHEBI:9334 CHEBI
D012460 MESH_DESCRIPTOR_UI
5339 PUBCHEM_CID
4840 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Azulfidine HUMAN PRESCRIPTION DRUG LABEL 1 0013-0101 TABLET 500 mg ORAL NDA 14 sections
Azulfidine HUMAN PRESCRIPTION DRUG LABEL 1 0013-0102 TABLET, DELAYED RELEASE 500 mg ORAL NDA 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0796 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 10544-288 TABLET 500 mg ORAL ANDA 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 33261-756 TABLET 500 mg ORAL ANDA 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 43353-495 TABLET 500 mg ORAL NDA AUTHORIZED GENERIC 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 50090-0086 TABLET 500 mg ORAL NDA AUTHORIZED GENERIC 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 50090-2013 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 50268-730 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 59762-0104 TABLET, DELAYED RELEASE 500 mg ORAL NDA AUTHORIZED GENERIC 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 59762-5000 TABLET 500 mg ORAL NDA AUTHORIZED GENERIC 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 63629-5688 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 68071-4215 TABLET 500 mg ORAL ANDA 13 sections
SULFASALAZINE HUMAN PRESCRIPTION DRUG LABEL 1 68788-9021 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0185 TABLET 500 mg ORAL ANDA 13 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1829 TABLET 500 mg ORAL NDA authorized generic 14 sections
Sulfasalazine HUMAN PRESCRIPTION DRUG LABEL 1 70518-2342 TABLET 500 mg ORAL ANDA 13 sections